Showing results (121-130 of 223) with videos related to
Sort By:
Pageof 23
The New Microbiologica|February 26, 2013
When phylogenetic analysis complements the epidemiological investigation: a case of HIV-2 infection, ItalyMassimo Ciccozzi, Annapaola Callegaro, Alessandra Lo Presti, et al.AIDS (London, England)|May 8, 2025
Comparable gut mucosal breakdown and microbial translocation in severe COVID-19 with and without HIV infectionSabrina Marozin, Valeria Bono, Martina Mazzoccoli, et al.AIDS (London, England)|September 10, 2002
Early and late effects of highly active antiretroviral therapy: a 2 year follow-up of antiviral-treated and antiviral-naive chronically HIV-infected patientsMario Clerici, Elena Seminari, Franco Maggiolo, et al.AIDS Reviews|June 26, 2018
A Comprehensive Development Agenda on Tenofovir Alafenamide in Clinical PracticeAntonio Di Biagio, Niccolò Riccardi, Stefano Rusconi, et al.Journal of Global Antimicrobial Resistance|October 13, 2025
96-week real-world effectiveness of bictegravir/emtricitabine/tenofovir alafenamide in HIV-infected adults with pre-existing NRTI resistance: A retrospective cohort studyLaura Mezzogori, Marco Muccio, Riccardo Schiavoni, et al.The New Microbiologica|January 7, 2009
Decrease of methicillin resistant Staphylococcus aureus prevalence after introduction of a surgical antibiotic prophylaxis protocol in an Italian hospitalEmanuele Nicastri, Sebastiano Leone, Nicola Petrosillo, et al.The Journal of Antimicrobial Chemotherapy|August 24, 2007
Sex issues in HIV-1-infected persons during highly active antiretroviral therapy: a systematic reviewEmanuele Nicastri, Sebastiano Leone, Claudio Angeletti, et al.HIV Clinical Trials|March 18, 2017
Efficacy and safety of emtricitabine/tenofovir alafenamide (FTC/TAF) vs. emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) as a backbone for treatment of HIV-1 infection in virologically suppressed adults: subgroup analysis by third agent of a randomized, double-blind, active-controlled phase 3 trialFrank A Post, Yazdan Yazdanpanah, Gabriel Schembri, et al.Plos One|June 28, 2016
Response to First-Line Ritonavir-Boosted Protease Inhibitors (PI/r)-Based Regimens in HIV Positive Patients Presenting to Care with Low CD4 Counts: Data from the Icona Foundation CohortAntonella d'Arminio Monforte, Alessandro Cozzi-Lepri, Franco Maggiolo, et al.Iscience|January 8, 2024
Association between SARS-CoV-2 RNAemia, skewed T cell responses, inflammation, and severity in hospitalized COVID-19 people living with HIVMatteo Augello, Valeria Bono, Roberta Rovito, et al.Pageof 23